Supplementary Figure S1 from CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Supplementary Figure S2 from CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma2024
2. 2Supplementary Figure S2 from CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma2024
3. 3Supplemental Figure 3 from <i>CDKN2A/B</i> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition2024
4. 4Supplemental Figure 3 from <i>CDKN2A/B</i> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition2024
5. 5Figure S1-S14, Table S1-S2 & S4-S6 from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach2024